8-K

Date: May 20, 2016

DIMENSION THERAPEUTICS, INC.

/s/ Jean Franchi

Jean Franchi

Chief Financial Officer

0001193125-16-597650.txt : 20160520 0001193125-16-597650.hdr.sgml : 20160520 20160520163103 ACCESSION NUMBER: 0001193125-16-597650 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160519 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20160520 DATE AS OF CHANGE: 20160520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dimension Therapeutics, Inc. CENTRAL INDEX KEY: 0001592288 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463942159 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37601 FILM NUMBER: 161666543 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-401-0011 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 d168596d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 19, 2016

Dimension Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE

001-37601

46-3942159

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

840 Memorial Drive, 4th Floor

Cambridge, MA

02139

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code (617) 401-0011

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07

Submission of Matters to a Vote of Security Holders.

At its Annual Meeting of Stockholders held on May 19, 2016 (the “Annual Meeting”), the stockholders of Dimension Therapeutics, Inc., a Delaware corporation (the “Company”) voted on the following matters, which are described in detail in the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on April 8, 2016: (i) to elect two Class I directors, namely Drs. Alan B. Colowick, M.P.H., M.D. and Georges Gemayel, Ph.D., to hold office until the 2019 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal (“Proposal 1”) and (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016 (“Proposal 2”).

The Company’s stockholders approved the nominees recommended for election in Proposal 1 at the Annual Meeting.

Stockholders voted for directors as follows:


Class I Director Nominee	For		Abstain/Withheld		Broker Non-Votes
Alan B. Colowick, M.P.H., M.D.		20,915,911		1,440,754		221,045
Georges Gemayel, Ph.D.		20,852,201		1,504,464		221,045

The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: 22,575,154 voted for, 1,534 shares voted against and 1,022 shares abstained from voting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.